HF-158K1 by HighField Biopharmaceuticals for Bladder Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Bladder Cancer.

Inari promotes Kevin Strange to CFO

Kevin Strange, incoming Inari Medical CFO Permission granted by Inari Medical Name: Kevin Strange New title: CFO, Inari Medical Previous title: Senior vice president of

August 2, 2024

Autoimmune Afib; Inappropriate ICD Shocks Down; Dissolving Cardiac Sensors

FDA approved expanded use of inclisiran (Leqvio) for primary hyperlipidemia atop its existing indications of atherosclerotic cardiovascular and heterozygous familial hypercholesterolemia, Novartis announced. An estimate

July 12, 2023

In North Carolina, a radical experiment targets social determinants of health with fresh produce and safe housing

Late last summer, Elizabeth Jacques brought her youngest daughter, Elena, for a medical checkup. At the time, Jacques and her family were experiencing housing instability

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.